11 September 2018
Visiongain has launched a new pharma report: In-Vitro Diagnostics World Market Report : Point of Care, Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Molecular Diagnostics, Flow Cytometry, Infectious Diseases, Diabetes, Cardiology, Autoimmune Diseases, Renal Diseases, Pharmacogenomics, HIV/AIDS, Reagent & Kits, Instruments, Data Management Software & Services, Hospitals, Laboratories, Home Care Testing, Research Institutes, Blood Glucose Testing, Infectious Disease Testing, Rapid Coagulation Testing, Cholesterol Testing, Pregnancy Testing, Basic Metabolic Panel, Electrolyte Panel, Liver Profile, Lipid Profile, Thyroid Function Test, ELISA, Immuno-PCR, Rapid Test, Western Blot, Enzyme linked Immunospot Assay
In vitro diagnostic (IVD) tests are medical assays performed on bodily fluids or tissues, as a diagnostic tool for a range of clinical disorders. The information obtained from such tests may act as a key factor in the decision making of a patient’s particular treatment plan. Examples of tests currently performed today include measuring the concentrations of various chemical and biochemical components, counting cells, measuring physical properties of the sample, microscopic examination of cells and other structures or preparing biological cultures. The generally positive outlook for the IVD industry has led to a large amount of merger and acquisition activity over previous years. These market trends are set to continue as the larger industry leaders look to consolidate power in an industry which is set to be worth $78.4bn by 2020.
The lead analyst of the report commented "Strengths in the IVD market primarily results from patient demographics. The rise in the global aging population will bear witness to an increasing incidence of age-related diseases, such as cardiovascular disease and cancer. This in turn has fuelled demand for advanced diagnostic testing equipment, capable of providing accurate clinical diagnoses, which allows for earlier medical intervention.
In addition, technological innovations in this field have introduced increasingly miniaturised and automated devices into the marketplace, which has given rise to a new range of condition-specific tests. Furthermore, continued research and development in IVD has allowed the discovery of new biomarkers, which has expanded the clinical application of IVD testing."
Leading companies featured in the report include Abbott Diagnostics, Agilent Technologies, Becton, Dickinson and Company (BD), BioMerieux, Bio-Rad, Danaher Corporation, DiaSorin Diagnostics s.p.a, Roche Diagnostics, Siemens Diagnostics, Sysmex Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.